Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

  1. Grande, E.
  2. Arranz, J.Á.
  3. De Santis, M.
  4. Bamias, A.
  5. Kikuchi, E.
  6. del Muro, X.G.
  7. Park, S.H.
  8. De Giorgi, U.
  9. Alekseev, B.
  10. Mencinger, M.
  11. Izumi, K.
  12. Schutz, F.A.
  13. Puente, J.
  14. Li, J.-R.
  15. O'Donnell, P.H.
  16. Kalebasty, A.R.
  17. Ye, D.
  18. Mariathasan, S.
  19. Bene-Tchaleu, F.
  20. Bernhard, S.
  21. Lee, C.
  22. Davis, I.D.
  23. Galsky, M.D.
Revista:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Any de publicació: 2024

Volum: 25

Número: 1

Pàgines: 29-45

Tipus: Article

DOI: 10.1016/S1470-2045(23)00540-5 GOOGLE SCHOLAR